Handelsavisen
prelaunch
Companies Healthcare CNVI.V
CN
CNVI.V TSX Venture Advanced Medical Equipment & Technology

Cnvi.V

$0,26
Open in Charts → Attach watcher ⌖
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
26,9M CAD
P/E
EV / Rev
Div yield
Op margin
-217,5 %
ROE
113,8 %
Net margin
-224,9 %
Debt / equity
-1,10
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

CNVI.V operates in the Advanced Medical Equipment & Technology industry, providing specialized medical devices and solutions to healthcare providers and patients.

Business. CNVI.V operates in the Advanced Medical Equipment & Technology industry, providing specialized medical devices and solutions to healthcare providers and patients.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target1,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
1,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
113,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CNVI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CNVI.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CNVI.V operates in the Advanced Medical Equipment & Technology industry, providing specialized medical devices and solutions to healthcare providers and patients.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with total liabilities of CAD 30.5 million and total equity of CAD -18.0 million, resulting in a debt-to-equity ratio of -1.1. Despite holding CAD 5.8 million in cash and equivalents, the company's liquidity is constrained by its CAD 19.9 million in long-term debt, and its operating cash flow of CAD -25.1 million indicates significant cash outflows from operations. The current ratio of 1.01 suggests the company is barely able to cover its short-term obligations with its current assets.

    Profitability is a major concern, as the company reported a net loss of CAD 20.5 million and an operating loss of CAD 19.8 million in the latest period. Return on equity (ROE) is positive at 1.14%, but this is misleading due to the negative equity base, and return on assets (ROA) is negative at -1.65%, indicating poor asset utilization. The company's gross profit of CAD 7.6 million is insufficient to cover operating expenses, highlighting inefficiencies in cost management.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to regional economic or regulatory risks, though specific geographic breakdowns are not available in the current dataset.

    Growth appears to be under pressure, with no clear revenue growth trajectory provided in the data. The company's free cash flow of CAD -19.9 million and capital expenditures of CAD -183,000 suggest limited reinvestment capacity and ongoing operational challenges. Analysts have assigned a mean price target of CAD 1.00, but the absence of strong buy ratings and the presence of only one buy recommendation indicate cautious sentiment.

    The company faces significant liquidity and solvency risks, with a negative net cash position after subtracting total debt. The risk of dilution is currently low, but the company's negative equity and high debt levels could necessitate equity financing in the future, potentially leading to share dilution. No recent events or filings are disclosed in the provided data to suggest immediate changes in the company's risk profile.

    The company's recent financial performance and risk profile suggest a challenging outlook. The absence of strong buy ratings and the negative operating cash flow indicate that the company may struggle to attract investor confidence without significant operational improvements or restructuring.

    Key takeaways
    • CNVI.V is operating at a significant net loss, with a negative return on assets and a high debt-to-equity ratio.
    • The company's liquidity is constrained by its negative net cash position and high debt levels.
    • Analysts have assigned a mean price target of CAD 1.00, but the absence of strong buy ratings suggests cautious sentiment.
    • The company's revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
    • The company's free cash flow is negative, and capital expenditures are minimal, indicating limited reinvestment capacity.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,26
    Market cap
    $28.5M
    Enterprise value
    $42.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$18.0M
    Net cash
    -$14.1M
    Current ratio
    1.0
    Debt / equity
    -1.1
    ROA
    -1.6%
    ROE
    1.1%
    Cash conversion
    122.0%
    CapEx / revenue
    -2.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$1,00 · Median $1,00
    Low $1,00High $1,00
    Operating income · consensus-27,6M CAD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,00
    Mean$1,00
    Median$1,00
    High$1,00
    Spot$0,26
    +284.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-217,5 %Bottom quartile
    Net Margin-224,9 %Bottom quartile
    ROE113,8 %Best in class
    Capex / Rev-2,0 %Above median
    D/E-1,10Best in class
    Cash Conv1,22Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • CNVI.V Market data — financials · 2026-05-27
    • Conavi Medical Corp Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CNVI.VCanonical
    TSX Venture · CAD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage